The PubMed citation identifies the ABLATION trial as a randomized controlled study comparing Biatrial Maze versus Left Atrial Maze ablation during cardiac valve surgery for patients with persistent atrial fibrillation. The journal is Circulation, with an electronic publication date of 2026 Nov 16 and a print date of 2026 Nov 17. The DOI is provided in the record. That is the extent of outcome information in the supplied source; the PubMed page copy provided here does not include the abstract or data tables. Short, direct fact: no efficacy or safety endpoints are reported in the excerpt we received.
Longer sentence for context: because the supplied PubMed content omits the study abstract and full text, investigators' reported endpoints—such as freedom from atrial fibrillation, sinus rhythm at predefined time points, stroke, all-cause mortality, pacemaker implantation rates, or rehospitalization—are not available for review in this record, and any attempt to summarize effect sizes or comparative safety would require accessing the full article.
The PubMed entry lists a large multicenter group of authors and affiliations predominantly from Chinese cardiovascular surgery centers. The document labels the study type as a Randomized Controlled Trial. Investigators reported include first authors Zhongchen Li and Chunyu Yu among many coauthors; institutional affiliations span national cardiovascular research centers and regional cardiac surgery departments. The record identifies the trial by its title—Biatrial Versus Left Atrial Maze Ablation During Cardiac Valve Surgery for Persistent Atrial Fibrillation: The ABLATION Trial—but the entry does not include explicit trial registration numbers or funding statements in the excerpt shown.
The citation metadata is clear. What is missing is the granular description of randomization procedures, stratification variables, or surgeon/operator experience metrics; the PubMed snippet does not report these elements.
The supplied PubMed content lacks crucial methodological details. The source text did not report: inclusion or exclusion criteria, sample size or power calculations, randomization sequence generation or concealment, blinding (if any), the precise lesion sets used in the Biatrial Maze and Left Atrial Maze arms, energy modality (cryothermal, radiofrequency, bipolar, or other), intraoperative anticoagulation protocols, or perioperative antiarrhythmic strategies.
Endpoints are similarly absent. The excerpt did not report the primary endpoint or secondary endpoints; there is no presentation of effect estimates, confidence intervals, P values, or Kaplan-Meier curves. Safety outcomes—operative mortality, stroke, bleeding, conduction disturbances requiring pacemaker implantation, and other procedure-related complications—are not included in the record provided.
I note a clinical consequence: without the reported endpoints and results, clinicians cannot determine whether biatrial lesions offered incremental rhythm benefit over left atrial lesions, nor can they weigh potential increases in conduction system injury or other harms.
Which patient subgroups—longstanding persistent versus recently persistent atrial fibrillation—benefit more from a biatrial approach? The PubMed excerpt does not say.
Does adding right-sided lesions increase the risk of permanent pacemaker implantation or prolong cross-clamp time to a clinically meaningful degree? The record provided does not include operative duration or conduction-event data.
How did the trial define and adjudicate recurrence of atrial fibrillation—ECG at clinic visits, ambulatory monitoring, continuous implantable monitoring—or both? Not reported here.
What was the follow-up interval for rhythm assessment, and were there prespecified time points such as 3, 6, and 12 months? The PubMed entry excerpt does not include follow-up duration.
Without these details, treatment decisions based on the ABLATION title alone would be premature.
Investigators reported the ABLATION trial in Circulation with full bibliographic details present on PubMed. To move from citation to clinical interpretation, clinicians and guideline authors should retrieve the full-text article—either via institutional subscription, journal website, or interlibrary loan—where the methods, endpoints, statistical analyses, and results will be presented. The PubMed record in the supplied material lacks the abstract and outcome tables that are necessary for evidence synthesis.
Limitations documented in the provided source: absence of abstract and outcome data in the supplied PubMed content. That specific omission prevents this summary from reporting any trial findings, numerical results, or methodological specifics. Remaining unanswered clinical questions include comparative rhythm efficacy, safety trade-offs including pacemaker rates, operative time differences, monitoring strategy, and subgroup effects; these must be resolved by consulting the full published article.
Practical note for readers: if you require immediate guidance on whether to favor a Biatrial Maze or Left Atrial Maze lesion set during valve surgery for persistent atrial fibrillation, consult the full Circulation article for the ABLATION trial before changing practice. The PubMed entry alone—without abstract or results—does not permit evidence-based decision-making.